Abstract
Objective To observe the efficacy of intravitreal injection of conbercept for macular edema secondary to retinal vein occlusion (RVO). Methods A case-control retrospective study. The data of 52 patients with macular edema secondary to RVO from Jan. 2016 to Dec. 2018 in Shanxi Province Eye Hospital were analyzed. All patients were treated with intravitreal conbercept injection, dose of 0.5 mg or 0.05 mL, in the 3+ pro renata(PRN) project. The followed up time was 6 months. Results The best corrected visual acuity (BCVA) at 1, 2, 3 and 6 months after treatment were better than that before treatment (t=13.010, 15.980, 7.530, 4.051, P<0.05). The thickness of central macula after treatment was lower than that before treatment (t=17.92, 12.32, 5.58, 0.41, P<0.05). During the treatment and follow-up, there was no serious complication such as vitreous hemorrhage, retinal detachment, persistent high intraocular pressure or endophthalmitis. Conclusion Intravitreal injection of conbercept is effective in the treatment of macular edema secondary to RVO, which can improve vision and reduce macular edema. Key words: Macular edema, secondary; Conbercept, injection, intravitreal; Retinal vein occlusion
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Chinese Journal of Ocular Trauma and Occupational Eye Disease
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
